Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF

Detalles Bibliográficos
Autores principales: Wang, Hongquan, Wu, Shuang, Wang, Yan, Tang, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334757/
https://www.ncbi.nlm.nih.gov/pubmed/35856565
http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0299
_version_ 1784759175511801856
author Wang, Hongquan
Wu, Shuang
Wang, Yan
Tang, Bo
author_facet Wang, Hongquan
Wu, Shuang
Wang, Yan
Tang, Bo
author_sort Wang, Hongquan
collection PubMed
description
format Online
Article
Text
id pubmed-9334757
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Compuscript
record_format MEDLINE/PubMed
spelling pubmed-93347572022-08-09 Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF Wang, Hongquan Wu, Shuang Wang, Yan Tang, Bo Cancer Biol Med Editorial Compuscript 2022-07-15 2022-07-21 /pmc/articles/PMC9334757/ /pubmed/35856565 http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0299 Text en Copyright: © 2022, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0 (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle Editorial
Wang, Hongquan
Wu, Shuang
Wang, Yan
Tang, Bo
Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
title Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
title_full Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
title_fullStr Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
title_full_unstemmed Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
title_short Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF
title_sort rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ese3/ehf
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334757/
https://www.ncbi.nlm.nih.gov/pubmed/35856565
http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0299
work_keys_str_mv AT wanghongquan rosiglitazonedisruptspancreaticductaladenocarcinomaprogressionbyactivatingthetumorsuppressorese3ehf
AT wushuang rosiglitazonedisruptspancreaticductaladenocarcinomaprogressionbyactivatingthetumorsuppressorese3ehf
AT wangyan rosiglitazonedisruptspancreaticductaladenocarcinomaprogressionbyactivatingthetumorsuppressorese3ehf
AT tangbo rosiglitazonedisruptspancreaticductaladenocarcinomaprogressionbyactivatingthetumorsuppressorese3ehf

Ejemplares similares